Fadi Massoud

Summary

Country: Canada

Publications

  1. ncbi Switching cholinesterase inhibitors in older adults with dementia
    Fadi Massoud
    Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, Service de Geriatrie, Montreal, Quebec, Canada
    Int Psychogeriatr 23:372-8. 2011
  2. ncbi Pharmacological treatment of Alzheimer disease
    Fadi Massoud
    Internist Geriatrician, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec
    Can J Psychiatry 56:579-88. 2011
  3. ncbi The nature of episodic memory deficits in MCI with and without vascular burden
    Sylvia Villeneuve
    Research Center, Institut Universitaire de Geriatrie de Montreal, Montreal, Canada
    Neuropsychologia 49:3027-35. 2011
  4. ncbi [Alzheimer Disease]
    Fadi Massoud
    Hopital Notre Dame, Service de Geriatrie, 1560, Sherbrooke Est, Montreal, Québec H2L 2M1
    Can Fam Physician 53:50-4. 2007
  5. ncbi A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes
    Claudie Charbonneau
    Centre hospitalier de l Université de Montréal Research Center Hôtel Dieu, Montreal, Quebec, Canada
    Curr Med Res Opin 24:3287-94. 2008
  6. ncbi Mild cognitive impairment subcategories depend on the source of norms
    Geneviève Arsenault-Lapierre
    Bloomfield Centre for Research on Aging, Lady Davis Institute of Medical Research, Sir B Davis Jewish General Hospital, Montreal, QC, Canada
    J Clin Exp Neuropsychol 33:596-603. 2011
  7. ncbi The profile of executive functioning in amnestic mild cognitive impairment: disproportionate deficits in inhibitory control
    Erin K Johns
    1Department of Psychology Centre for Research in Human Development, Concordia University, Montreal, Quebec
    J Int Neuropsychol Soc 18:541-55. 2012
  8. ncbi The role of functional assessment as an outcome measure in antidementia treatment
    Fadi Massoud
    Service de Geriatrie, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, QC, Canada
    Can J Neurol Sci 34:S47-51. 2007
  9. ncbi Update on the pharmacological treatment of Alzheimer's disease
    Fadi Massoud
    Department of Medicine, University of Montreal, Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, Service de Geriatrie, 1560 Sherbrooke Est, Montreal, Quebec, H2L 4M1
    Curr Neuropharmacol 8:69-80. 2010

Collaborators

Detail Information

Publications9

  1. ncbi Switching cholinesterase inhibitors in older adults with dementia
    Fadi Massoud
    Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, Service de Geriatrie, Montreal, Quebec, Canada
    Int Psychogeriatr 23:372-8. 2011
    ..These agents differ in their individual mechanisms of action and pharmacokinetic properties. Switching ChEIs can be a reasonable option in cases of intolerance or lack of clinical benefit...
  2. ncbi Pharmacological treatment of Alzheimer disease
    Fadi Massoud
    Internist Geriatrician, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec
    Can J Psychiatry 56:579-88. 2011
    ..To review the different pharmacological approaches to the cognitive, functional, and behavioural manifestations of Alzheimer disease (AD)...
  3. ncbi The nature of episodic memory deficits in MCI with and without vascular burden
    Sylvia Villeneuve
    Research Center, Institut Universitaire de Geriatrie de Montreal, Montreal, Canada
    Neuropsychologia 49:3027-35. 2011
    ..Overall, results indicate that the presence of vascular burden in MCI is associated with selective impairment of strategic memory processes...
  4. ncbi [Alzheimer Disease]
    Fadi Massoud
    Hopital Notre Dame, Service de Geriatrie, 1560, Sherbrooke Est, Montreal, Québec H2L 2M1
    Can Fam Physician 53:50-4. 2007
    ..Alzheimer disease (AD) is the most common form of dementia. There have been many advances in the pharmacological treatment of AD in recent years. This article discusses 2 of these advances: vascular prevention and a new molecule, memantine...
  5. ncbi A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes
    Claudie Charbonneau
    Centre hospitalier de l Université de Montréal Research Center Hôtel Dieu, Montreal, Quebec, Canada
    Curr Med Res Opin 24:3287-94. 2008
    ..It is unclear whether treatment with cholinesterase inhibitors (ChEIs), which has been found to slow disease progression in AD patients, has similar benefits in vascular forms of dementia...
  6. ncbi Mild cognitive impairment subcategories depend on the source of norms
    Geneviève Arsenault-Lapierre
    Bloomfield Centre for Research on Aging, Lady Davis Institute of Medical Research, Sir B Davis Jewish General Hospital, Montreal, QC, Canada
    J Clin Exp Neuropsychol 33:596-603. 2011
    ..In general, local norms were more stringent than published norms. We discuss the implications of these results for MCI diagnosis and categorization...
  7. ncbi The profile of executive functioning in amnestic mild cognitive impairment: disproportionate deficits in inhibitory control
    Erin K Johns
    1Department of Psychology Centre for Research in Human Development, Concordia University, Montreal, Quebec
    J Int Neuropsychol Soc 18:541-55. 2012
    ..jins, 2012, 18, 541-555)...
  8. ncbi The role of functional assessment as an outcome measure in antidementia treatment
    Fadi Massoud
    Service de Geriatrie, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, QC, Canada
    Can J Neurol Sci 34:S47-51. 2007
    ..There are no functional scales specifically designed for assessment of subjects with non-AD cognitive impairment. Scales specifically developed for Mild Cognitive Impairment and other dementias are needed...
  9. ncbi Update on the pharmacological treatment of Alzheimer's disease
    Fadi Massoud
    Department of Medicine, University of Montreal, Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, Service de Geriatrie, 1560 Sherbrooke Est, Montreal, Quebec, H2L 4M1
    Curr Neuropharmacol 8:69-80. 2010
    ..Finally, it will introduce future therapeutic options currently under study...